| Literature DB >> 33432286 |
Fahmida Begum Mina1, Mutasim Billah1,2, Sumon Karmakar3, Sabuj Das1, Md Siddikur Rahman1, Md Faruk Hasan1,2, Uzzal Kumar Acharjee2.
Abstract
PURPOSE: The pandemic of coronavirus disease 2019 (COVID-19) has cost numerous lives and induced tremendous mental stress among people. The purpose of this research was to determine anxiety and depression levels, clinical features, and the connections between demographic variables and depression prevalence as well as anxiety prevalence among reported COVID-19 cases in Bangladesh.Entities:
Keywords: Anxiety; Bangladesh; COVID-19; Clinical characteristics; Depression
Year: 2021 PMID: 33432286 PMCID: PMC7787928 DOI: 10.1007/s10389-020-01445-2
Source DB: PubMed Journal: Z Gesundh Wiss ISSN: 0943-1853
Sociodemographic characteristics of individuals with COVID-19 (n = 153)
| Variables | Findings |
|---|---|
| Age (years) | 39.43 ± 17.59 |
| Age groups | |
| < 30 | 43 (28.1) |
| 31–40 | 37 (24.2) |
| 41–50 | 27 (17.7) |
| 51–60 | 23 (15.0) |
| > 60 | 23 (15.0) |
| Sex | |
| Male | 110 (72) |
| Female | 43 (28) |
| Residence | |
| Urban | 86 (56.2) |
| Semi urban | 87 (24.2) |
| Rural | 30 (19.6) |
| Education | |
| No formal schooling | 21 (13.7) |
| Primary | 31 (20.4) |
| SSC or similar | 38 (24.8) |
| HSC or similar | 17(11.1) |
| Graduation | 34 (22.2) |
| Post-graduation | 12(7.8) |
| Occupation | |
| Private service | 45 (29.4) |
| Government service | 35 (22.9) |
| Businessman | 31 (20.3) |
| Housewife | 21 (13.7) |
| Student | 6(3.9) |
| Unemployed | 15(9.8) |
| 50 (32.7) | |
| 17 (17.7) | |
| Monthly income (BDT) | 30,000 (16000–50,000) |
| < 25,000 | 55 (39.9) |
| 25,000 to 50,000 | 53 (38.4) |
| 50,001 to 75,000 | 15 (10.9) |
| > 75,000 | 15(10.9) |
| Number of family members living in the same house | |
| One | 12(7.8) |
| Two to four | 66 (43.1) |
| ≥ Four | 75 (49.1) |
| Suspected place of contact | |
| Workplace | 72 (47.1) |
| Market place/bazar | 29 (18.9) |
| Home | 15(9.8) |
| Hospital | 12(7.8) |
| Mosque | 6(3.9) |
| Unknown | 19 (12.5) |
| Travel history (outside country) | 25 (1.2) |
Continuous data is expressed as mean ± SD or median (IQR) and frequency data is expressed as counts (percentage)
Preventive measures practices of individuals with COVID-19 (n = 153)
| Variables | Findings |
|---|---|
| Social distancing practice | |
| Always | 132 (86.3) |
| Not always | 17 (11.1) |
| No | 4 (2.6) |
| Putting up mask | |
| Always | 128 (83.7) |
| Not always | 17 (11.1) |
| No | 8 (5.2) |
| Washing hands | |
| Frequent | 126 (82.4) |
| Not frequent | 21 (13.7) |
| No | 6 (3.9) |
| Refrain from touching eyes, nose or mouth | |
| Frequent | 127 (83) |
| Not frequent | 19 (12.4) |
| No | 7 (4.6) |
| Covering nose and mouth with bent elbow or tissue while coughing or sneezing | |
| Frequent | 124 (81) |
| Not frequent | 21 (13.7) |
| No | 8 (5.3) |
Data is expressed as counts (percentage)
Clinical features of patients with COVID-19 (n = 153)
| Variables | Findings |
|---|---|
| Presentation | |
| Asymptomatic | 19 (12.4) |
| Symptomatic | 134 (87.6) |
| Symptoms | |
| Fever | 121 (79) |
| Cough | 90 (58.8) |
| Myalgia | 37 (24.2) |
| Breathlessness | 36 (23.5) |
| Sore throat | 33 (21.6) |
| Fatigue | 30 (19.6) |
| Headache | 21(13.7) |
| Nausea and/or vomiting | 18(11.8) |
| Runny nose | 15 (9.8) |
| Chest pain | 14(9.2) |
| Diarrhea | 13(8.5) |
| Stuffy nose | 5(3.2) |
| ARDS | 4(2.6) |
| Oral ulcer | 4(2.6) |
| Conjunctivitis | 3(1.9) |
| Investigation | |
| Chest X-ray | |
| Done in | 39 (25.4) |
| Normal | 18(46.2) |
| Bilateral pneumonia | 14(35.9) |
| Unilateral pneumonia | 7(17.9) |
| CT scan of chest | |
| Done in | 5 (3.3) |
| Bilateral pneumonia | 5(100) |
| Co-morbidities | |
| Present | 64 (41.8) |
| Endocrine disease | 35 (22.9) |
| Respiratory disease | 22 (14.4) |
| Cardiovascular disease | 17 (11.1) |
| Hematological disease | 1 (0.6) |
Data is expressed as counts (percentage)
Management and clinical status of persons with COVID-19 (n = 153)
| Variables | Findings |
|---|---|
| Treatment history | |
| Antibiotic | 98 (64) |
| Hydroxychloroquine | 42 (27.5) |
| Oxygen | 12 (7.8) |
| Antiviral | 9 (5.9) |
| Corticosteroid | 4 (2.6) |
| Clinical status | |
| Outcome present | 29 (18.9) |
| Currently under treatment | 124 (81.1) |
| Treatment place | |
| Home isolation | 56 (45.2) |
| Being treated in COVID-19 hospital | 49 (39.5) |
| Being treated in general hospital | 19 (15.3) |
| Outcome | |
| Discharged without complication | 21 (72.4) |
| Died | 8 (27.6) |
Data is expressed as counts (percentage)
Anxiety and depression among persons with COVID-19 (n = 145)
| Variables | Findings |
|---|---|
| Anxiety disorder | |
| Prevalence | 92 (63.5) |
| Severity | |
| Mild anxiety (GAD7: 5–9) | 54 (58.7) |
| Moderate anxiety (GAD7: 10–14) | 17 (18.5) |
| Severe (GAD7: 15–21) | 21 (22.8) |
| Depressive disorder | |
| Prevalence | 82 (56.6) |
| Severity | |
| Mild (PHQ9: 5–9) | 40(48.8) |
| Moderate (PHQ9: 10–14) | 31 (37.8) |
| Moderately severe (15–19) | 4 (4.9) |
| Severe (20–27) | 7 (8.5) |
| Distributions | |
| Both anxiety and depression | 73 (50.3) |
| Only anxiety | 19 (13.2) |
| Only depression | 9 (6.3) |
| None | 44 (30.3) |
Data is expressed as counts (percentage)